JP2020506159A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506159A5 JP2020506159A5 JP2018550764A JP2018550764A JP2020506159A5 JP 2020506159 A5 JP2020506159 A5 JP 2020506159A5 JP 2018550764 A JP2018550764 A JP 2018550764A JP 2018550764 A JP2018550764 A JP 2018550764A JP 2020506159 A5 JP2020506159 A5 JP 2020506159A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- administered
- cycle
- pharmaceutical composition
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 52
- 201000011510 cancer Diseases 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 40
- -1 2', 3-dimethyl- [2,4'-bipyridine] -5-yl Chemical group 0.000 claims description 14
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 201000009030 Carcinoma Diseases 0.000 claims description 8
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 8
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 229960003301 nivolumab Drugs 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 229960002621 pembrolizumab Drugs 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 2
- XJRMWHFALRWZTE-UHFFFAOYSA-N 2-pyridin-3-ylpyrazine Chemical compound C1=CN=CC(C=2N=CC=NC=2)=C1 XJRMWHFALRWZTE-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 4
- WYGLXTDVKXMJAE-UHFFFAOYSA-N 2-methyl-4-(3-methylpyridin-2-yl)pyridine Chemical compound CC1=NC=CC(=C1)C1=NC=CC=C1C WYGLXTDVKXMJAE-UHFFFAOYSA-N 0.000 description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022139650A JP2022174157A (ja) | 2017-02-14 | 2022-09-02 | 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール |
| JP2024095809A JP2024133495A (ja) | 2017-02-14 | 2024-06-13 | 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762458640P | 2017-02-14 | 2017-02-14 | |
| US62/458,640 | 2017-02-14 | ||
| US201862616682P | 2018-01-12 | 2018-01-12 | |
| US62/616,682 | 2018-01-12 | ||
| PCT/IB2018/050846 WO2018150312A1 (en) | 2017-02-14 | 2018-02-12 | Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022139650A Division JP2022174157A (ja) | 2017-02-14 | 2022-09-02 | 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020506159A JP2020506159A (ja) | 2020-02-27 |
| JP2020506159A5 true JP2020506159A5 (enExample) | 2021-03-25 |
Family
ID=61526841
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550764A Pending JP2020506159A (ja) | 2017-02-14 | 2018-02-12 | 組み合わせでのＷｎｔ阻害剤および抗ＰＤ−１抗体分子の投与スケジュール |
| JP2022139650A Withdrawn JP2022174157A (ja) | 2017-02-14 | 2022-09-02 | 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール |
| JP2024095809A Pending JP2024133495A (ja) | 2017-02-14 | 2024-06-13 | 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022139650A Withdrawn JP2022174157A (ja) | 2017-02-14 | 2022-09-02 | 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール |
| JP2024095809A Pending JP2024133495A (ja) | 2017-02-14 | 2024-06-13 | 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11406633B2 (enExample) |
| EP (1) | EP3582811B1 (enExample) |
| JP (3) | JP2020506159A (enExample) |
| KR (2) | KR20190112801A (enExample) |
| CN (2) | CN110267682A (enExample) |
| AU (1) | AU2018221557C1 (enExample) |
| CA (1) | CA3051989A1 (enExample) |
| IL (1) | IL268341B2 (enExample) |
| MX (1) | MX2019009630A (enExample) |
| RU (1) | RU2767533C2 (enExample) |
| TW (1) | TWI771372B (enExample) |
| WO (1) | WO2018150312A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| CA3007671A1 (en) * | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| US20210395351A1 (en) * | 2018-09-27 | 2021-12-23 | Musc Foundation For Research Development | Pharmaceutical combination for the treatment of cancer |
| WO2020236078A1 (en) * | 2019-05-22 | 2020-11-26 | Agency For Science, Technology And Research | Pharmaceutical combination |
| CN113134090B (zh) * | 2021-03-26 | 2022-05-17 | 武汉大学中南医院 | 一种抗肿瘤药物组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| US20160303137A1 (en) * | 2015-04-20 | 2016-10-20 | Indiana University Research And Technology Corporation | Dual pi3k and wnt pathway inhibition as a treatment for cancer |
| CN104767366A (zh) * | 2015-04-21 | 2015-07-08 | 永济新时速电机电器有限责任公司 | 辅助变流器和车辆 |
| US20180153884A1 (en) * | 2015-05-31 | 2018-06-07 | Curegenix Corporation | Combination compositions for immunotherapy |
-
2018
- 2018-02-12 WO PCT/IB2018/050846 patent/WO2018150312A1/en not_active Ceased
- 2018-02-12 CN CN201880011133.5A patent/CN110267682A/zh active Pending
- 2018-02-12 EP EP18708210.2A patent/EP3582811B1/en active Active
- 2018-02-12 MX MX2019009630A patent/MX2019009630A/es unknown
- 2018-02-12 RU RU2019128843A patent/RU2767533C2/ru active
- 2018-02-12 CN CN202311777725.7A patent/CN117752784A/zh active Pending
- 2018-02-12 AU AU2018221557A patent/AU2018221557C1/en not_active Ceased
- 2018-02-12 US US16/482,836 patent/US11406633B2/en active Active
- 2018-02-12 CA CA3051989A patent/CA3051989A1/en active Pending
- 2018-02-12 JP JP2018550764A patent/JP2020506159A/ja active Pending
- 2018-02-12 KR KR1020197026087A patent/KR20190112801A/ko not_active Ceased
- 2018-02-12 KR KR1020247000317A patent/KR20240007717A/ko not_active Ceased
- 2018-02-14 TW TW107105427A patent/TWI771372B/zh active
-
2019
- 2019-07-29 IL IL268341A patent/IL268341B2/en unknown
-
2022
- 2022-06-29 US US17/809,623 patent/US20230063366A1/en not_active Abandoned
- 2022-09-02 JP JP2022139650A patent/JP2022174157A/ja not_active Withdrawn
-
2024
- 2024-06-13 JP JP2024095809A patent/JP2024133495A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506159A5 (enExample) | ||
| US11964941B2 (en) | 5-Bromo-indirubins | |
| EP3173100B1 (en) | Therapeutic combination comprising a cdks inhibitor and oxaliplatin | |
| JP2022058398A (ja) | Ｂｒａｆ－ｖ６００関連疾患の治療に使用するためのｐｌｘ－８３９４またはｐｌｘ－７９０４ | |
| ES2573515T3 (es) | Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados | |
| JP2024133475A5 (enExample) | ||
| JP2018109022A5 (enExample) | ||
| JP2016528162A5 (enExample) | ||
| RU2019128843A (ru) | Режим дозирования ингибитора wnt и молекулы антитела к pd-1 в комбинации | |
| CN110996927A (zh) | 复发性胶质母细胞瘤(rgbm)的治疗方法 | |
| TWI544920B (zh) | Ｎ－羥基－４－｛２－［３－（ｎ，ｎ－二甲基胺基甲基）苯並呋喃－２－基羰基胺基］乙氧基｝苯甲醯胺之新穎投藥法 | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| TW201914592A (zh) | 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| CN109069500A (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| TW202214243A (zh) | 西奧羅尼聯合免疫檢查點抑製劑在抗腫瘤治療中的應用 | |
| JP2016525104A5 (enExample) | ||
| JP2014513144A (ja) | 進行性又は転移性固形悪性腫瘍を含む固形悪性腫瘍の治療方法 | |
| CN108601778A (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
| AU2014236370C1 (en) | 5-bromo-indirubins | |
| CN109876000A (zh) | 帕布昔利布在黏膜恶性黑色素瘤中的应用 | |
| TW202406907A (zh) | 哌𠯤類化合物在製備用於聯合放療治療腫瘤的藥物中的用途 | |
| JP2019038797A5 (enExample) | ||
| TW202110454A (zh) | Cdk4/6抑制劑與vegfr抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| CN113893256A (zh) | 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用 | |
| JP2015531355A (ja) | 腫瘍治療のための薬剤組成物及びその適用 |